# Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

> **NCT04356742** · PHASE3 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 198 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin 10mg
- **DRUG:** Placebo
- **DRUG:** Evogliptin 5mg
- **DRUG:** Metformin≥1000mg

## Key facts

- **NCT ID:** NCT04356742
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-26
- **Primary completion:** 2022-02-23
- **Final completion:** 2022-02-23
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2022-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04356742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04356742, "Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04356742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*